Collaboration will evaluate INOVIO's INO-5412 (INO-5401 plus INO-9012) in combination with Akeso's cadonilimab as a potential treatment for glioblastoma (GBM), the most common and aggressive ...
For asymptomatic people without known risks, the downsides and uncertainties of multi-cancer early detection testing could ...
A new study finds that popular GLP-1 drugs used to treat diabetes and obesity show new promise in fighting multiple substance ...
The earliest stage of drug discovery is governed by a simple constraint: there are far more possible drug-like molecules than any pharmaceutical laboratory could ever test. A new deep learning system, ...
Their makers claim they can detect dozens of cancer types — but some scientists say they could be missing many cancers or ...
Researchers at the Peter Doherty Institute for Infection and Immunity (Doherty Institute) have developed a world-first ...
The Veterinary Hospital Managers Association (VHMA) has announced newly earned. Certifications. Seven professionals have earned the Certified Veterinary Practice Manager (CVPM) designation, and 5 have ...
Christina Gentry, DVM, DACVM, discusses dermatologic signs that a patient is in need of immediate attention, including ...
TD Cowen 46th Annual Health Care Conference March 3, 2026 11:10 AM ESTCompany ParticipantsRoopal Thakkar - Executive VP of Research ...
JPLoft advances enterprise automation with intelligent AI agents that streamline operations, enhance decision-making, ...
INOVIO , and Akeso, Inc. (9926.HK) ("Akeso") today announced that they have entered into a clinical trial collaboration and supply agreement to evaluate INO-5412, INOVIO's DNA immunotherapy candidate, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results